10-K: Bio-Path Holdings Reports 2024 Results, Highlights Clinical Progress and Obesity Program

Bio-Path Holdings' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical programs, including progress in AML, lymphoma, solid tumors, and its newly initiated obesity program.

Summary

• Bio-Path Holdings, a clinical-stage oncology and obesity-focused company, released its 10-K filing for the year ended December 31, 2024.
• The company is developing RNAi nanoparticle drugs using its DNAbilize technology.
• Key drug candidates include BP1001 (prexigebersen) for AML, BP1002 for lymphoma and AML, BP1003 for pancreatic and lung cancer, and BP1001-A for solid tumors and obesity.
• Interim data from a Phase 2 clinical trial of prexigebersen in combination with decitabine and venetoclax for AML showed promising remission rates.
• Enrollment in cohorts 1 and 2 of the Phase 2 trial is expected to continue, with completion planned for 2026.
• A Phase 1 clinical trial of BP1002 for lymphoma and CLL was discontinued due to enrollment challenges, but a Phase 1/1b trial for AML is ongoing.
• BP1003 is in IND-enabling studies for pancreatic cancer and NSCLC, with plans to file an IND and initiate a Phase 1 study.
• Preclinical work suggests BP1001-A could be a potential treatment for obesity and related metabolic diseases, with animal studies underway and a Phase 1 trial planned for 2025.
• The company had $1.2 million in cash on hand as of December 31, 2024, and will require additional capital to fund operations.
• Research and development expenses were $7.3 million for 2024, compared to $11.6 million in 2023.
• The company reported a net loss of $9.9 million for 2024, compared to a net loss of $16.1 million for 2023.
• The company's common stock was delisted from The Nasdaq Capital Market and commenced trading on the OTCQB Venture Market on February 19, 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive clinical trial results and preclinical data, the company faces financial challenges, including limited cash and recurring losses. The delisting from Nasdaq is also a negative factor.

Positives

• Promising interim Phase 2 data for prexigebersen in AML combination therapy.
• Advancement of BP1002 Phase 1/1b clinical trial for AML.
• Positive preclinical data for BP1003 in solid tumor models.
• Preclinical validation of BP1001-A as a potential treatment for obesity and related metabolic diseases.
• Plans to pursue FDA expedited programs for Fast Track designation for prexigebersen.

Negatives

• Discontinuation of BP1002 Phase 1 clinical trial for lymphoma and CLL due to enrollment challenges.
• Delisting of the company's common stock from The Nasdaq Capital Market.
• Limited cash on hand ($1.2 million as of December 31, 2024) and the need for additional capital to fund operations.
• Recurring operating losses and accumulated deficit.

Risks

• The company's ability to raise additional capital when needed.
• The success of clinical trials and the ability to obtain regulatory approval for drug candidates.
• Competition from other pharmaceutical and biotechnology companies.
• Reliance on third parties for manufacturing and conducting clinical trials.
• Potential product liability claims and intellectual property disputes.
• The volatility of the trading price of the company's common stock.

Future Outlook

The company plans to continue enrollment in cohorts 1 and 2 of the Phase 2 trial of prexigebersen in AML, with completion planned for 2026. It also intends to file an IND and initiate a Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors. The company plans to initiate a first-in-human Phase 1 clinical trial in 2025 to further validate safety, measure pharmacokinetics and establish dosing for potential pivotal trials for BP1001-A as a potential treatment for obesity and related metabolic diseases.

Industry Context

The company operates in the highly competitive pharmaceutical and biotechnology industry, facing competition from larger companies with greater resources. The company is focused on developing targeted therapies for oncology and obesity, areas with significant unmet medical needs.

Comparison to Industry Standards

• The company's approach of using RNAi nanoparticle drugs and DNAbilize technology is a novel approach in the field of targeted therapies.
• The company's clinical trial results for prexigebersen in AML combination therapy are promising compared to historical remission rates with LDAC treatment alone.
• The company faces competition from other companies developing therapies for AML, lymphoma, solid tumors, and obesity, including companies developing novel treatments and technology platforms based on modalities and technology that may be similar to ours.
• The company's ability to compete effectively will depend on the safety and effectiveness of its drug candidates, the timing of their entry into the market, and the availability of reimbursement coverage.

Stakeholder Impact

• Shareholders: Dilution from potential future equity offerings, reliance on stock appreciation for returns.
• Employees: Potential impact on job security due to financial constraints.
• Patients: Potential for new treatment options for cancer and obesity.
• Creditors: Risk of delayed payments due to financial constraints.

Next Steps

• Continue enrollment in cohorts 1 and 2 of the Phase 2 trial of prexigebersen in AML.
• Pursue FDA expedited programs for Fast Track designation for prexigebersen.
• File an IND and initiate a Phase 1 study of BP1003 in patients with refractory, metastatic solid tumors.
• Initiate a first-in-human Phase 1 clinical trial in 2025 to further validate safety, measure pharmacokinetics and establish dosing for potential pivotal trials for BP1001-A as a potential treatment for obesity and related metabolic diseases.

Key Dates

Keywords

Bio-Path Holdings, RNAi nanoparticle, DNAbilize, Prexigebersen, BP1001, BP1002, BP1003, BP1001-A, AML, Lymphoma, Pancreatic cancer, NSCLC, Obesity, Clinical trial, Drug development